North America Cardiac Marker Testing Market

North America Cardiac Marker Testing Market Size

The size of the North America cardiac marker testing market was worth USD 1.29 billion in 2024. The North America market is anticipated to grow at a CAGR of 7.89% from 2025 to 2033 and be worth USD 2.56 billion by 2033 from USD 1.39 billion in 2025.

MARKET DRIVERS

Rising Aging Population and Growing Investments in Cardiac Care Are Driving the North America ECMO Market

Growing funds and investments by different organizations to surge the research and clinical trials rise in the aging population In 2016, the number of older people aged 65 years and above was nearly 8.5%. By the end of 2050, the count is expected to surge over 17%, according to the National Institutes of Health (NIH). The rise in the aging population is associated with increased cardiovascular diseases like cardiac failure, myocardial infarction, and angina pectoris. The rising popularity of point of care testing and the rapid development of healthcare infrastructure accelerates the growth. Also, the government and research institutes determined efforts to deal with severe cardiac diseases and growing research and development activities relevant to the market are to boost the market in the region.

MARKET RESTRAINTS

Limited Test Kit Availability and High Entry Barriers for New Players Are Hindering the North America ECMO Market

Less availability of test kits and high competition among the key players in the market, the entrance for new players in the market cannot mark prints effectively are hindering the market growth in the region. The expensive nature of the tests associated with some tests' less specificity is acting as a barrier to market growth in the area.

REPORT COVERAGE

COUNTRY LEVEL ANALYSIS

North America held the largest share of the global cardiac marker testing market. Factors such as public-private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars are the key factors aiding the growth of the markets.

The United States is ruling the market in this region based on the increasing obese population, which has become a health challenge in the last few years. Every sixth person is obese, and the number of obese people in the region has been doubled, according to WHO. 1.9 billion Adults are suffering from obesity, and over 650 were obese. Obesity is concerned with the growing number of cardiovascular diseases like congestive heart failure and more. Surging government observation in minimizing the length of the stay of the patient and different modes of patient care like an emergency room, homecare and near-patient testing and advancements in healthcare for personalized medicine has surged the significance of cardiac makers for fast, efficient, and quality maintenance of the health stimulating the market growth in the region.

KEY MARKET PLAYERS

Promising Companies leading the North America Cardiac Marker Testing Market Profiled in the report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.

MARKET SEGMENTATION

This research report on the North America cardiac marker testing market is segmented and sub-segmented into the following categories.

By Type

• Troponin I & T

• CK-MB

• Myoglobin

• BNP

• HsCRP

By Product

• Reagent

• Instrument

  • Chemiluminescence

  • Immunofluorescence

  • Immunochromatography

  • ELISA

By Disease

• Acute Coronary Syndrome

• Myocardial Infarction

• Congestive Heart Failure

By Testing

• Lab

• Point of Care (POC)

By Country

• United States
• Canada
• Mexico
• Rest of North America